Companies
Artiva Biotherapeutics
allogeneic NK (AB-101) — off-the-shelf cord-blood doses.
- Country
- United States
FDA IND
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $741.9 million in aggregate gross proceeds raised from inception through June 30, 2026 | stocktitan.net |
| Capacity | capability to produce enough AlloNK to treat over 1,000 autoimmunity patients annually at current San Diego facility | s203.q4cdn.com · artivabio.com |
| Production site | 9,000 square-foot, cGMP-compliant cell production center in San Diego, California | artivabio.com · sec.gov |
| Regulatory approval | FDA Fast Track designation for AlloNK in refractory rheumatoid arthritis | investors.artivabio.com · artivabio.com · sec.gov |
| Headcount | 106 employees as of March 31, 2026 | stockanalysis.com |
| Revenue | No revenue from product sales as of June 30, 2026 | stocktitan.net |
Independent sources: investors.artivabio.com · s203.q4cdn.com · sec.gov · stockanalysis.com · stocktitan.net
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| NK-cell & CAR-NK therapy | therapeutics-platforms | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.